Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Romania

 

HBI 2023: The outpatient differential

For years there has been a trend towards using outpatient services wherever possible - to improve patient outcomes, to better use an increasingly scarce workforce, and to increase cost efficiency. On the “Outpatient differential” panel at HBI 2023, how this push looks across the world was a key topic for discussion.
July 12, 2023

Mubadala-backed M42 buying Diaverum “for $2bn+”

Swedish multinational dialysis firm Diaverum is being bought by M42, a joint venture between Abu Dhabi sovereign wealth fund Mubadala Investment Co and AI firm G42, for a reported $2bn-$2.5bn. Diaverum’s CEO tells HBI the deal offers further opportunities to develop its digital strategies, and international expansion. 
April 19, 2023

Digital health booming in CEE

Digital health is booming in Central and Eastern Europe (CEE), boosted by several countries in the region introducing major policy initiatives to integrate telehealth solutions and digitise their health systems. CEE-based multinational law firm Kinstellar spells this out in its latest ‘Current eHealth trends in CEE and Turkey’ report.
April 14, 2023

Diaverum deal: An analysis

Last week the news broke that Abu Dhabi sovereign wealth fund Mubadala Investment Co might be set to buy Swedish multinational dialysis firm Diaverum for a reported $2.5bn. HBI speaks to an operator source who thinks this would be a good price for the seller - and hears why some investors are switched off by dialysis.
April 6, 2023

Inflow of nurses to top five European markets

This week, HBI looks at the annual inflow of nurses from abroad to the big five Western European markets - the United Kingdom, Germany, France, Italy, and Spain - using public data from OECD. Those looking for an outlier need look no further than the UK.
March 17, 2023

Cinven looks to take Synlab private as Covid boost falters

Frankfurt-listed Synlab could be about to be taken private following a non-binding full takeover offer earlier this week. With its full year results released yesterday and facing questions about its plans, HBI asks market experts what they think of the move.
March 17, 2023

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.
April 28, 2022
Older posts
Newer posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us